Analyst Ratings For Athenex Inc (NASDAQ:ATNX)
Today, LADENBURG THALM/SH SH initiated coverage on Athenex Inc (NASDAQ:ATNX) with a Buy with a price target of $27.00.
There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Athenex Inc (NASDAQ:ATNX) is Buy with a consensus target price of $25.00 per share, a potential 93.65% upside.
Some recent analyst ratings include
- 10/25/2018-Athenex Inc (NASDAQ:ATNX) has coverage initiated with a Buy rating and $27.00 price target
- 3/6/2018-Athenex Inc (NASDAQ:ATNX) has coverage initiated with a Buy ➝ Buy rating and $30.00 price target
- 9/19/2017-Athenex Inc (NASDAQ:ATNX) has coverage initiated with a Buy rating and $36.00 price target
- 9/18/2017-Athenex Inc (NASDAQ:ATNX) has coverage initiated with a Outperform ➝ Outperform rating and $25.00 price target
- 9/14/2017-Athenex Inc (NASDAQ:ATNX) has coverage initiated with a Outperform ➝ Outperform rating and $35.00 price target
- On 10/15/2018 Jinn Wu, Director, bought 12,500 with an average share price of $13.47 per share and the total transaction amounting to $168,375.00.
- On 9/27/2018 Johnson Yiu Nam Lau, CEO, bought 2,000 with an average share price of $15.66 per share and the total transaction amounting to $31,320.00.
- On 9/6/2018 Jinn Wu, Director, bought 2,500 with an average share price of $16.09 per share and the total transaction amounting to $40,225.00.
- On 9/6/2018 Johnson Yiu Nam Lau, CEO, bought 5,000 with an average share price of $15.84 per share and the total transaction amounting to $79,200.00.
- On 8/29/2018 Song-Yi Zhang, Director, sold 51,029 with an average share price of $16.61 per share and the total transaction amounting to $847,591.69.
- On 8/27/2018 Song-Yi Zhang, Director, sold 53,439 with an average share price of $17.11 per share and the total transaction amounting to $914,341.29.
- On 8/24/2018 Song-Yi Zhang, Director, sold 23,137 with an average share price of $17.17 per share and the total transaction amounting to $397,262.29.
About Athenex Inc (NASDAQ:ATNX)
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom. In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients. Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs. The company was founded in 2003 and is headquartered in Buffalo, New York.
Recent Trading Activity for Athenex Inc (NASDAQ:ATNX)
Shares of Athenex Inc closed the previous trading session at 12,83 +0,46 3,72 % with 12.41 shares trading hands.